Physician profile
John Biedenbach
NPI 1174878979
$2,211.24
in general payments reported to CMS, 2019-2025
20 companies · $608 in 2025
The $608 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $395 · 2023: $260 · 2024: $503 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,366 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,365.72 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $661.70 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $253.65 | 2022-2025 | |
| Novo Nordisk INC | $219.07 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.33 | 2021-2025 | Jardiance |
| Pfizer INC. | $153.06 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $143.93 | 2021-2022 | |
| Lilly USA, LLC | $120.34 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Daiichi Sankyo INC. | $98.41 | 2021-2022 | |
| Dexcom, INC. | $55.03 | 2024-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $52.04 | 2021 | |
| Currax Pharmaceuticals LLC | $46.25 | 2022-2023 | Contrave, Onzetra Xsail |
| E.R. Squibb & Sons, L.L.C. | $42.97 | 2022-2023 | Camzyos |
| Biohaven Pharmaceutical Holding Company LTD. | $39.79 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $35.20 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $29.78 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $24.37 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $22.75 | 2025 | Evenity |
| Glaxosmithkline, LLC. | $21.86 | 2024 | Shingrix |
| Phathom Pharmaceuticals, INC. | $14.76 | 2024 | Voquezna |
| Eisai INC. | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Biedenbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.